Seeking Alpha

Recently public Receptos (RCPT +19.5%) soars on a Credit Suisse initiation (Outperform, price...

Recently public Receptos (RCPT +19.5%) soars on a Credit Suisse initiation (Outperform, price target $21). Analyst Ravi Mehrotra says RPC1063 — the company's "key asset" — has a clinical profile that puts it "in a different 'bucket'" than Novartis' Gilenya when it comes to treating multiple sclerosis.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs